Cargando…

Discrimination between Complete versus Non-Complete Pathologic Response to Neoadjuvant Therapy Using Ultrasensitive Mutation Analysis: A Proof-of-Concept Study in BRCA1-Driven Breast Cancer Patients

Neoadjuvant chemotherapy (NACT) for breast cancer (BC) often results in pathologic complete response (pCR), i.e., the complete elimination of visible cancer cells. It is unclear whether the use of ultrasensitive genetic methods may still detect residual BC cells in complete responders. Breast carcin...

Descripción completa

Detalles Bibliográficos
Autores principales: Sokolenko, Anna P., Moiseyenko, Fedor V., Iyevleva, Aglaya G., Ivantsov, Alexandr O., Dolmatov, Georgiy D., Shelekhova, Ksenia V., Gulo, Elizaveta V., Topal, Anastasya X., Artemieva, Elizaveta V., Abduloeva, Nuriniso H., Rysev, Nikita A., Barsova, Daria A., Levchenko, Natalia V., Volkov, Nikita M., Egorenkov, Vitaliy V., Moiseyenko, Vladimir M., Imyanitov, Evgeny N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9914941/
https://www.ncbi.nlm.nih.gov/pubmed/36768191
http://dx.doi.org/10.3390/ijms24031870
_version_ 1784885785511591936
author Sokolenko, Anna P.
Moiseyenko, Fedor V.
Iyevleva, Aglaya G.
Ivantsov, Alexandr O.
Dolmatov, Georgiy D.
Shelekhova, Ksenia V.
Gulo, Elizaveta V.
Topal, Anastasya X.
Artemieva, Elizaveta V.
Abduloeva, Nuriniso H.
Rysev, Nikita A.
Barsova, Daria A.
Levchenko, Natalia V.
Volkov, Nikita M.
Egorenkov, Vitaliy V.
Moiseyenko, Vladimir M.
Imyanitov, Evgeny N.
author_facet Sokolenko, Anna P.
Moiseyenko, Fedor V.
Iyevleva, Aglaya G.
Ivantsov, Alexandr O.
Dolmatov, Georgiy D.
Shelekhova, Ksenia V.
Gulo, Elizaveta V.
Topal, Anastasya X.
Artemieva, Elizaveta V.
Abduloeva, Nuriniso H.
Rysev, Nikita A.
Barsova, Daria A.
Levchenko, Natalia V.
Volkov, Nikita M.
Egorenkov, Vitaliy V.
Moiseyenko, Vladimir M.
Imyanitov, Evgeny N.
author_sort Sokolenko, Anna P.
collection PubMed
description Neoadjuvant chemotherapy (NACT) for breast cancer (BC) often results in pathologic complete response (pCR), i.e., the complete elimination of visible cancer cells. It is unclear whether the use of ultrasensitive genetic methods may still detect residual BC cells in complete responders. Breast carcinomas arising in BRCA1 mutation carriers almost always carry alterations of the TP53 gene thus providing an opportunity to address this question. The analysis of consecutive BC patients treated by NACT revealed a higher pCR rate in BRCA1-driven vs. BRCA1-wildtype BCs (13/24 (54%) vs. 29/192 (15%), p < 0.0001). Twelve pre-/post-NACT tissue pairs obtained from BRCA1 mutation carriers were available for the study. While TP53 mutation was identified in all chemonaive tumors, droplet digital PCR (ddPCR) analysis of the post-NACT tumor bed revealed the persistence of this alteration in all seven pCR-non-responders but in none of five pCR responders. Eleven patients provided to the study post-NACT tissue samples only; next-generation sequencing (NGS) analysis revealed mutated TP53 copies in all six cases without pCR but in none of five instances of pCR. In total, TP53 mutation was present in post-NACT tissues in all 13 cases without pCR, but in none of 10 patients with pCR (p < 0.000001). Therefore, the lack of visible tumor cells in the post-NACT tumor bed is indeed a reliable indicator of the complete elimination of transformed clones. Failure of ultrasensitive methods to identify patients with minimal residual disease among pCR responders suggests that the result of NACT is a categorical rather than continuous variable, where some patients are destined to be cured while others ultimately fail to experience tumor eradication.
format Online
Article
Text
id pubmed-9914941
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99149412023-02-11 Discrimination between Complete versus Non-Complete Pathologic Response to Neoadjuvant Therapy Using Ultrasensitive Mutation Analysis: A Proof-of-Concept Study in BRCA1-Driven Breast Cancer Patients Sokolenko, Anna P. Moiseyenko, Fedor V. Iyevleva, Aglaya G. Ivantsov, Alexandr O. Dolmatov, Georgiy D. Shelekhova, Ksenia V. Gulo, Elizaveta V. Topal, Anastasya X. Artemieva, Elizaveta V. Abduloeva, Nuriniso H. Rysev, Nikita A. Barsova, Daria A. Levchenko, Natalia V. Volkov, Nikita M. Egorenkov, Vitaliy V. Moiseyenko, Vladimir M. Imyanitov, Evgeny N. Int J Mol Sci Article Neoadjuvant chemotherapy (NACT) for breast cancer (BC) often results in pathologic complete response (pCR), i.e., the complete elimination of visible cancer cells. It is unclear whether the use of ultrasensitive genetic methods may still detect residual BC cells in complete responders. Breast carcinomas arising in BRCA1 mutation carriers almost always carry alterations of the TP53 gene thus providing an opportunity to address this question. The analysis of consecutive BC patients treated by NACT revealed a higher pCR rate in BRCA1-driven vs. BRCA1-wildtype BCs (13/24 (54%) vs. 29/192 (15%), p < 0.0001). Twelve pre-/post-NACT tissue pairs obtained from BRCA1 mutation carriers were available for the study. While TP53 mutation was identified in all chemonaive tumors, droplet digital PCR (ddPCR) analysis of the post-NACT tumor bed revealed the persistence of this alteration in all seven pCR-non-responders but in none of five pCR responders. Eleven patients provided to the study post-NACT tissue samples only; next-generation sequencing (NGS) analysis revealed mutated TP53 copies in all six cases without pCR but in none of five instances of pCR. In total, TP53 mutation was present in post-NACT tissues in all 13 cases without pCR, but in none of 10 patients with pCR (p < 0.000001). Therefore, the lack of visible tumor cells in the post-NACT tumor bed is indeed a reliable indicator of the complete elimination of transformed clones. Failure of ultrasensitive methods to identify patients with minimal residual disease among pCR responders suggests that the result of NACT is a categorical rather than continuous variable, where some patients are destined to be cured while others ultimately fail to experience tumor eradication. MDPI 2023-01-18 /pmc/articles/PMC9914941/ /pubmed/36768191 http://dx.doi.org/10.3390/ijms24031870 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sokolenko, Anna P.
Moiseyenko, Fedor V.
Iyevleva, Aglaya G.
Ivantsov, Alexandr O.
Dolmatov, Georgiy D.
Shelekhova, Ksenia V.
Gulo, Elizaveta V.
Topal, Anastasya X.
Artemieva, Elizaveta V.
Abduloeva, Nuriniso H.
Rysev, Nikita A.
Barsova, Daria A.
Levchenko, Natalia V.
Volkov, Nikita M.
Egorenkov, Vitaliy V.
Moiseyenko, Vladimir M.
Imyanitov, Evgeny N.
Discrimination between Complete versus Non-Complete Pathologic Response to Neoadjuvant Therapy Using Ultrasensitive Mutation Analysis: A Proof-of-Concept Study in BRCA1-Driven Breast Cancer Patients
title Discrimination between Complete versus Non-Complete Pathologic Response to Neoadjuvant Therapy Using Ultrasensitive Mutation Analysis: A Proof-of-Concept Study in BRCA1-Driven Breast Cancer Patients
title_full Discrimination between Complete versus Non-Complete Pathologic Response to Neoadjuvant Therapy Using Ultrasensitive Mutation Analysis: A Proof-of-Concept Study in BRCA1-Driven Breast Cancer Patients
title_fullStr Discrimination between Complete versus Non-Complete Pathologic Response to Neoadjuvant Therapy Using Ultrasensitive Mutation Analysis: A Proof-of-Concept Study in BRCA1-Driven Breast Cancer Patients
title_full_unstemmed Discrimination between Complete versus Non-Complete Pathologic Response to Neoadjuvant Therapy Using Ultrasensitive Mutation Analysis: A Proof-of-Concept Study in BRCA1-Driven Breast Cancer Patients
title_short Discrimination between Complete versus Non-Complete Pathologic Response to Neoadjuvant Therapy Using Ultrasensitive Mutation Analysis: A Proof-of-Concept Study in BRCA1-Driven Breast Cancer Patients
title_sort discrimination between complete versus non-complete pathologic response to neoadjuvant therapy using ultrasensitive mutation analysis: a proof-of-concept study in brca1-driven breast cancer patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9914941/
https://www.ncbi.nlm.nih.gov/pubmed/36768191
http://dx.doi.org/10.3390/ijms24031870
work_keys_str_mv AT sokolenkoannap discriminationbetweencompleteversusnoncompletepathologicresponsetoneoadjuvanttherapyusingultrasensitivemutationanalysisaproofofconceptstudyinbrca1drivenbreastcancerpatients
AT moiseyenkofedorv discriminationbetweencompleteversusnoncompletepathologicresponsetoneoadjuvanttherapyusingultrasensitivemutationanalysisaproofofconceptstudyinbrca1drivenbreastcancerpatients
AT iyevlevaaglayag discriminationbetweencompleteversusnoncompletepathologicresponsetoneoadjuvanttherapyusingultrasensitivemutationanalysisaproofofconceptstudyinbrca1drivenbreastcancerpatients
AT ivantsovalexandro discriminationbetweencompleteversusnoncompletepathologicresponsetoneoadjuvanttherapyusingultrasensitivemutationanalysisaproofofconceptstudyinbrca1drivenbreastcancerpatients
AT dolmatovgeorgiyd discriminationbetweencompleteversusnoncompletepathologicresponsetoneoadjuvanttherapyusingultrasensitivemutationanalysisaproofofconceptstudyinbrca1drivenbreastcancerpatients
AT shelekhovakseniav discriminationbetweencompleteversusnoncompletepathologicresponsetoneoadjuvanttherapyusingultrasensitivemutationanalysisaproofofconceptstudyinbrca1drivenbreastcancerpatients
AT guloelizavetav discriminationbetweencompleteversusnoncompletepathologicresponsetoneoadjuvanttherapyusingultrasensitivemutationanalysisaproofofconceptstudyinbrca1drivenbreastcancerpatients
AT topalanastasyax discriminationbetweencompleteversusnoncompletepathologicresponsetoneoadjuvanttherapyusingultrasensitivemutationanalysisaproofofconceptstudyinbrca1drivenbreastcancerpatients
AT artemievaelizavetav discriminationbetweencompleteversusnoncompletepathologicresponsetoneoadjuvanttherapyusingultrasensitivemutationanalysisaproofofconceptstudyinbrca1drivenbreastcancerpatients
AT abduloevanurinisoh discriminationbetweencompleteversusnoncompletepathologicresponsetoneoadjuvanttherapyusingultrasensitivemutationanalysisaproofofconceptstudyinbrca1drivenbreastcancerpatients
AT rysevnikitaa discriminationbetweencompleteversusnoncompletepathologicresponsetoneoadjuvanttherapyusingultrasensitivemutationanalysisaproofofconceptstudyinbrca1drivenbreastcancerpatients
AT barsovadariaa discriminationbetweencompleteversusnoncompletepathologicresponsetoneoadjuvanttherapyusingultrasensitivemutationanalysisaproofofconceptstudyinbrca1drivenbreastcancerpatients
AT levchenkonataliav discriminationbetweencompleteversusnoncompletepathologicresponsetoneoadjuvanttherapyusingultrasensitivemutationanalysisaproofofconceptstudyinbrca1drivenbreastcancerpatients
AT volkovnikitam discriminationbetweencompleteversusnoncompletepathologicresponsetoneoadjuvanttherapyusingultrasensitivemutationanalysisaproofofconceptstudyinbrca1drivenbreastcancerpatients
AT egorenkovvitaliyv discriminationbetweencompleteversusnoncompletepathologicresponsetoneoadjuvanttherapyusingultrasensitivemutationanalysisaproofofconceptstudyinbrca1drivenbreastcancerpatients
AT moiseyenkovladimirm discriminationbetweencompleteversusnoncompletepathologicresponsetoneoadjuvanttherapyusingultrasensitivemutationanalysisaproofofconceptstudyinbrca1drivenbreastcancerpatients
AT imyanitovevgenyn discriminationbetweencompleteversusnoncompletepathologicresponsetoneoadjuvanttherapyusingultrasensitivemutationanalysisaproofofconceptstudyinbrca1drivenbreastcancerpatients